A Phase I, Multiple-Dose, Open-Label, Crossover Study in Healthy Subjects to Assess the Effect of Dolutegravir (DTG) on the Pharmacokinetics (PK) of Cenicriviroc (CVC) and the Effect of CVC on the PK of DTG and on a Single Dose of Midazolam

Primary Objectives To evaluate the steady-state PK of CVC administered with and without DTG . To evaluate the steady-state PK of DTG administered with and without CVC . To evaluate the PK of a single dose of Midazolam administered with and without steady state CVC when both are administered orally. Secondary Objectives To evaluate the safety and tolerability of CVC administered with and without DTG. To evaluate the safety and tolerability of CVC administered with and without Midazolam.